Aquinnah Pharmaceuticals, Inc.
Publicly observedNewton, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Newton | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Aquinnah Pharmaceuticals, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | T6T9BUCQMDB1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Jun 2025Publicly observed
NIH SBIR/STTR award: Development of a novel oral brain penetrant therapeutic for ALS disease
USD 1,499,529.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jun 2025Publicly observed
NIH SBIR/STTR award: Development of a novel oral brain penetrant therapeutic for ALS disease
USD 1,499,212.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2018Publicly observed
NIH SBIR/STTR award: Development of a novel Alzheimer's disease therapeutic targeting tau
USD 997,942.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2018Publicly observed
NIH SBIR/STTR award: Development of a novel Alzheimer's disease therapeutic targeting tau
USD 998,691.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.